Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 6 (February 20), 2007: pp. 669-674
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.8197

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beer, T. M.
Right arrow Articles by Clow, F. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beer, T. M.
Right arrow Articles by Clow, F. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*1,25-DIHYDROXYCHOLECALCIFEROL
*DOCETAXEL
Medline Plus Health Information
*Prostate Cancer
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators

Tomasz M. Beer, Christopher W. Ryan, Peter M. Venner, Daniel P. Petrylak, Gurkamal S. Chatta, J. Dean Ruether, Charles H. Redfern, Louis Fehrenbacher, Mansoor N. Saleh, David M. Waterhouse, Michael A. Carducci, Daniel Vicario, Robert Dreicer, Celestia S. Higano, Frederick R. Ahmann, Kim N. Chi, W. David Henner, Alan Arroyo, Fong W. Clow

From the Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR; Columbia Presbyterian Medical Center, New York, NY; University of Pittsburgh, Pavillion Hellman Cancer Center, Pittsburgh, PA; Sharp HealthCare; San Diego Cancer Center, Vista; Kaiser Permanente Medical Center, Vallejo; Novacea Inc, South San Francisco, CA; Georgia Cancer Specialists, Tucker, GA; Oncology Hematology Care, Cincinnati; The Cleveland Clinic Foundation, Cleveland, OH; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Seattle Cancer Care Alliance, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Cross Cancer Institute, Edmonton; Tom Baker Cancer Centre, Calgary, Alberta; and the University of British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada

Address reprint requests to Tomasz M. Beer, MD, Department of Medicine, Oregon Health & Science University, Mail Code CR-145, 3181 SW Sam Jackson Park Rd, Portland, OR 97239; e-mail: beert{at}ohsu.edu

PURPOSE: To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel.

PATIENTS AND METHODS: Patients with progressive metastatic androgen-independent prostate cancer and adequate organ function received weekly docetaxel 36 mg/m2 intravenously for 3 weeks of a 4-week cycle combined with either 45 µg DN-101 or placebo taken orally 1 day before docetaxel. The primary end point was prostate-specific antigen (PSA) response within 6 months of enrollment, defined as a 50% reduction confirmed at least 4 weeks later.

RESULTS: Two hundred fifty patients were randomly assigned. Baseline characteristics were similar in both arms. Within 6 months, PSA responses were seen in 58% in DN-101 patients and 49% in placebo patients (P = .16). Overall, PSA response rates were 63% (DN-101) and 52% (placebo), P = .07. Patients in the DN-101 group had a hazard ratio for death of 0.67 (P = .04) in a multivariate analysis that included baseline hemoglobin and performance status. Median survival has not been reached for the DN-101 arm and is estimated to be 24.5 months using the hazard ratio, compared with 16.4 months for placebo. Grade 3/4 adverse events occurred in 58% of DN-101 patients and in 70% of placebo-treated patients (P = .07). Most common grade 3/4 toxicities for DN-101 versus placebo were neutropenia (10% v 8%), fatigue (8% v 16%), infection (8% v 13%), and hyperglycemia (6% v 12%).

CONCLUSION: This study suggests that DN-101 treatment was associated with improved survival, but this will require confirmation because survival was not a primary end point. The addition of weekly DN-101 did not increase the toxicity of weekly docetaxel.

Supported by Novacea Inc and sanofi-aventis.

Presented in part at the Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL; and at the European Cancer Conference (ECCO 13), October 30-November 3, 2005, Paris, France.

Oregon Health & Science University (OHSU) and Tomasz M. Beer have a significant financial interest in Novacea Inc, a company that may have a commercial interest in the results of this research and technology. This potential conflict was reviewed and a management plan approved by the OHSU conflict of interest in research committee and the integrity program oversight council was implemented.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • Could the Efficacy of Docetaxel in Prostate Cancer Patients Be Potentiated by Concomitant High-Dose Calcitriol Administration?
    Alfredo Berruti, Marcello Tucci, Alessandra Mosca, Mara Ardine, Massimiliano Poggio, Andrea Saini, Lucianna Russo, Federica Vana, and Luigi Dogliotti
    JCO 2008 26: 1900-1901 [Full Text]


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. Chen, G. Davey Smith, D. M. Evans, A. Cox, D. A. Lawlor, J. Donovan, W. Yuan, I. N. M. Day, R. M. Martin, A. Lane, et al.
Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review
Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 2874 - 2881.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
J. MOAN, A. DAHLBACK, Z. LAGUNOVA, E. CICARMA, and A. C. POROJNICU
Solar Radiation, Vitamin D and Cancer Incidence and Mortality in Norway
Anticancer Res, September 1, 2009; 29(9): 3501 - 3509.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
S. SRINIVAS and D. FELDMAN
A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer
Anticancer Res, September 1, 2009; 29(9): 3605 - 3610.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Bikle
Nonclassic Actions of Vitamin D
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 26 - 34.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
W. B. Grant
Vitamin D May Reduce Prostate Cancer Metastasis by Several Mechanisms Including Blocking Stat3
Am. J. Pathol., November 1, 2008; 173(5): 1589 - 1590.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. Bouillon, G. Carmeliet, L. Verlinden, E. van Etten, A. Verstuyf, H. F. Luderer, L. Lieben, C. Mathieu, and M. Demay
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Endocr. Rev., October 1, 2008; 29(6): 726 - 776.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Wang, H. Lian, Y. Zhao, M. A. Kauss, and S. Spindel
Vitamin D3 Induces Autophagy of Human Myeloid Leukemia Cells
J. Biol. Chem., September 12, 2008; 283(37): 25596 - 25605.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
M. F. Holick
Vitamin D and Sunlight: Strategies for Cancer Prevention and Other Health Benefits
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1548 - 1554.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
B. T. Kawasaki, E. M. Hurt, T. Mistree, and W. L. Farrar
Targeting Cancer Stem Cells with Phytochemicals
Mol. Interv., August 1, 2008; 8(4): 174 - 184.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
L. A. Mucci and D. Spiegelman
Vitamin D and Prostate Cancer Risk--A Less Sunny Outlook?
J Natl Cancer Inst, June 4, 2008; 100(11): 759 - 761.
[Full Text] [PDF]


Home page
Integr Cancer TherHome page
I. Cantor
Shedding Light on Vitamin D and Integrative Oncology
Integr Cancer Ther, June 1, 2008; 7(2): 81 - 89.
[Abstract] [PDF]


Home page
Clin. Cancer Res.Home page
S. Attia, J. Eickhoff, G. Wilding, D. McNeel, J. Blank, H. Ahuja, A. Jumonville, M. Eastman, D. Shevrin, M. Glode, et al.
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer
Clin. Cancer Res., April 15, 2008; 14(8): 2437 - 2443.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Berruti, M. Tucci, A. Mosca, M. Ardine, M. Poggio, A. Saini, L. Russo, F. Vana, and L. Dogliotti
Could the Efficacy of Docetaxel in Prostate Cancer Patients Be Potentiated by Concomitant High-Dose Calcitriol Administration?
J. Clin. Oncol., April 10, 2008; 26(11): 1900 - 1901.
[Full Text] [PDF]


Home page
JCOHome page
C. K. Daugherty, M. J. Ratain, E. J. Emanuel, A. T. Farrell, and R. L. Schilsky
Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials
J. Clin. Oncol., March 10, 2008; 26(8): 1371 - 1378.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. G. Schwartz
Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 478 - 483.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. Kaeding, J. Belanger, P. Caron, M. Verreault, A. Belanger, and O. Barbier
Calcitrol (1{alpha},25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells
Mol. Cancer Ther., February 1, 2008; 7(2): 380 - 390.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. M. Basch, M. R. Somerfield, T. M. Beer, M. A. Carducci, C. S. Higano, M. H.A. Hussain, and H. I. Scher
American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5313 - 5318.
[Abstract] [Full Text] [PDF]


Home page
JWatch Oncology and HematologyHome page
Improving Docetaxel's Activity in Advanced Prostate Cancer
Journal Watch Oncology and Hematology, March 5, 2007; 2007(305): 2 - 2.
[Full Text]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online